Resectable Non-small Cell Lung Cancer
Conditions
Brief summary
This study is an open-label, multicenter phase II clinical trial of adebelizumab combined with other anti-tumor therapies in patients with non-small cell lung cancer. The aim of this study was to evaluate the safety, tolerability and efficacy of adebelizumab combined with other anti-tumor therapies in patients with resectable non-small cell lung cancer ( NSCLC )
Interventions
DRUGAdebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection
Adebrelimab Injection combined with SHR-1826 Injection combined with SHR-8068 Injection
DRUGAdebrelimab Injection combined with HRS-7058 Capsule
Adebrelimab Injection combined with HRS-7058 Capsule
Sponsors
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
1. voluntarily participate in this clinical study, understand the research procedure and be able to sign the informed consent in writing ; 2. At the time of signing the informed consent form, the age is 18-70 years old ( including both ends ), both men and women can. The ECOG score was 0 or 1. 4. Patients with histopathologically or cytologically confirmed Stage II, IIIA, or select Stage IIIB (AJCC 9th edition) non-small cell lung cancer who are candidates for curative-intent R0 surgical resection. 5.Combined genetic requirements : non-squamous cell carcinoma subjects must undergo EGFR gene detection and ALK gene and or immunohistochemical detection. 6.Can provide tumor tissue specimens, which can be archived or freshly obtained specimens for biomarker detection. 7.According to the RECIST v1.1 standard, subjects must have measurable target lesions examined by CT or MRI. Tumor imaging evaluation was performed within 28 days before the first administration. 8.There is sufficient hematology and organ function, as defined by the results of laboratory tests, to be completed within 7 days prior to the first dose of treatment : 9.Women of childbearing age must have a serum pregnancy test within 7 days before the first administration, and the result is negative. Women of childbearing age and men whose partners are women of childbearing age must agree to use an efficient method of contraception from the date of signing the informed consent to at least 26 weeks ( female subjects ) or 14 weeks ( male subjects ) after the last administration.
Exclusion criteria
1. Small cell lung cancer ( SCLC ) and NSCLC mixed tumors confirmed by histology or cytology contain non-NSCLC pathological types such as small cell components. 3.Have previously received systematic anti-tumor therapy for non-small cell lung cancer other than this study ( including clinical research drugs ) ; 4.Participants who had received or planned to receive local treatment such as chest radiotherapy or ablation ;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pathological complete response (pCR) rate: pCR is defined as the absence of any residual tumor at the time of surgical resection. | All results are expected to be obtained in the last participant three months after surgery. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Event-free survival (EFS) | In view of the relatively stable postoperative condition, the preliminary plan was collected until the end of the 5-year follow-up of the last participant | EFS is defined as the time from the first dose to any of the following events: any progression of disease precluding surgery; progression or recurrent disease based on investigator assessment per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 after surgery; or death from any cause. |
| Disease-free survival (DFS) as assessed byinvestigator | In view of the relatively stable postoperative condition, the preliminary plan was collected until the end of the 5-year follow-up of the last participant | DFS is defined as the time from firste dose to any recurrence (local, locoregional, regional or distant), occurrence of new primary NSCLC, or death due to any cause, whichever occurs first. |
| Objective response rate (ORR): assessed by the investigator | In view of the relatively stable postoperative condition, the preliminary plan was collected until the end of the 5-year follow-up of the last participant | — |
| Overall Survival (OS) | In view of the relatively stable postoperative condition, the preliminary plan was collected until the end of the 5-year follow-up of the last participant | OS is defined as the time from first dose to death due to any cause. |
Countries
China
Contacts
CONTACTYanhua Huang
Outcome results
None listed